Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Agenus: Thoughts on Phase II Results for Prophage in Glioblastoma (AGEN, $2.91)

Reason for This Report
Agenus (AGEN) just issued an update on a phase II trial of Prophage G-100 combined with current…
Read more…